USUnited StatesHealthtentative
PDUFA dates: giredestrant (Roche, breast cancer), povetacicept (Vertex, IgA nephropathy), sevabertinib (Bayer, lung cancer)
Cluster of late-November FDA decisions on multibillion-dollar candidates.
- News
- 2/5
- Markets
- 4/5
- Overall
- 3/5

